It inhibits the epithelial-mesenchymal transition (EMT) process, downregulates MALAT1 expression in a dose- and time-dependent manner, promotes apoptosis, and inactivates the PI3K/Akt signaling pathway in the human prostate cancer cell line PC-3 (Lu et al., 2020). The gene discussed is AKT1; the disease is prostate carcinoma.